RxDoctor Payments Data

Christy Hill

Family · New Lexington, OHNPI 1275044604

Payments from drug & device makers

$5,170in general payments, 2019–2025

Across 317 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$792
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$328
  • Amgen$258
  • Otsuka America Pharmaceutical, Inc.$218
  • Corcept Therapeutics$188
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$5,12399%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,170 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$173
Medicare patients
15
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$58,936
JardianceEmpagliflozin40$38,352
FarxigaDapagliflozin Propanediol37$28,730
EliquisApixaban28$19,252
TrulicityDulaglutide15$18,319
LinzessLinaclotide30$16,685
Tresiba Flextouch U-200Insulin Degludec19$14,398
JanuviaSitagliptin Phosphate13$13,653
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,318
MyrbetriqMirabegron14$6,203
Albuterol Sulfate HfaAlbuterol Sulfate90$2,677
Potassium Chloride87$1,537
Omeprazole128$1,383
Gabapentin112$1,140
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$173$58,93652 claims
Boehringer IngelheimJardiance$74$38,35240 claims
AstraZenecaFarxiga, Breztri Aerosphere$792$37,04850 claims
PfizerEliquis$103$19,25228 claims
Lilly USA, LLCTrulicity$88$18,31915 claims
AbbVieLinzess, Synthroid$1,472$17,19148 claims
MerckJanuvia$77$13,65313 claims
Astellas Pharma US IncMyrbetriq$67$6,20314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.

Other family in New Lexington

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →